Nouscom announces appointment of Sarah Runswick as Senior Director of Clinical Science
We are thrilled to welcome Sarah Runswick as Senior Director of Clinical Science at Nouscom.
Sarah is an experienced global clinical scientist with over 20 years expertise in early and late stage oncology clinical trial development and delivery, including successful regulatory submission experience and leading investigator study strategy and programs. Sarah joined Nouscom as a Clinical Consultant from Medorci Clinical Consulting where she has been a Company Director and Founder for 5 years providing consulting services for Pharma, CROs and Biotechs including Aptus Clinical/Catalyst Clinical Research, Immetacyte, Artelo, AVACTA and Athenex. Recently, she was the study clinical lead for AstraZeneca’s pivotal Phase III POSEIDON trial in first line mNSCLC resulting in successful delivery and regulatory submissions of IMFINZI plus IMJUDO and chemotherapy in USA, EMA and Japan market approvals.
Prior to that, Sarah was a Director in Clinical Development at AstraZeneca where she was clinical study lead for the pivotal Phase III OLYMPIAD and was responsible for clinical data delivery, publication and key in successful submission activities leading to approvals for Lynparza in metastatic breast cancer. Additionally, she was responsible for the Clinical Science strategy for Faslodex Late Clinical Delivery team that successfully delivered the pivotal Phase III FALCON study leading to approval of Faslodex in estrogen receptor positive advanced breast cancer for postmenopausal women. She has led investigator sponsored strategy and programs for PARP inhibitors and Faslodex programs in early clinical development.
Before that, Sarah was a Technical expert in Genomics and has a strong background in bioinformatics and developing clinical biomarkers.
Sarah trained as a Cell Biologist at the University of Liverpool and held post-doctoral academic research posts at the University of Manchester with Wellcome and Medical Research Council in the United Kingdom.